We describe a data repository on heritable disorders of connective tissue (HDCT) assembled by 
| INTRODUCTION
The heritable disorders of connective tissue (HDCT) are a heterogeneous group of conditions caused by defects in the structure and synthesis of extracellular matrix elements such as collagen, elastin, muco-polysaccharides, and related biomolecules (McKusick, 1973) .
The genetic causes of many HDCT have been identified (Beyens et al., 2018; Byers et al., 2017; Dietz et al., 1991; Francomano, 2010; Francomano et al., 1987; Lee, Vitale, Superti-Furga, Steinmann, & Ramirez, 1991; Liberfarb et al., 2003; Malfait et al., 2017) . However, others are not well understood at the molecular level, most notably the hypermobile form of Ehlers-Danlos syndrome (EDS). Diagnostic criteria for this diverse family of disorders have evolved over the years since the present study was initiated (Beighton, 1970; Malfait et al., 2017) . Affected persons often present with features that do not clearly fit into a neat diagnostic category.
Defining the disease phenotypes for these rare disorders is a continuing challenge. Because connective tissue is ubiquitous in the human body, the hereditary HDCT affect multiple organ systems. Also challenging is the variability between individuals with the same diagnosis and among family members (inter-and intra-familial variability).
A third challenge is the evolving nature of the phenotype in a single individual over the lifespan, as patients report considerable temporal variation in symptoms. Early clinical studies suggested common features across the individual syndromes, but typically focused on a particular organ system manifestation. More recent studies have begun to document the multisystem nature of EDS (Castori et al., 2017) , but robust cluster analyses of large cohorts, ascertained using consistent methods, are needed. Another continuing need is for evaluation of the multiorgan system aspect of these disorders, and for comparison across HDCT diagnoses using standardized instruments.
To address the necessity for deeper characterization of these disorders, a cohort study was initiated in 2001 at the National Institute on Aging (NIA). Enrollment in the study continued through 2013. Recruitment focused on identifying patients across the spectrum of HDCT with clinical classification at the time of recruitment, extensive phenotyping, and collection and banking of bio-samples. Personnel and programmatic changes led to an end of the NIA intramural study in 2013, and patient organizations advocated for the development of a process to release the accumulated data to investigators in the academic community.
Our long-range program goals are to perform analyses of the complex multisymptom manifestations in the HDCT, to further enrich the data repository by developing discrete data from unstructured elements (e.g., narrative history and imaging), and to encourage the use of the data by other researchers. This article will provide a description of the full HDCT cohort and existing data elements, as well as the process by which data have been prepared for release.
| METHODS
The National Institute on Aging study Clinical and Molecular Manifestations of Heritable Disorders of Connective Tissue was designed to investigate the natural history of the most common HDCT. Emphasis was placed on the cardiovascular, musculoskeletal, and neurological complications of HDCT and the natural history of these complications.
The original study protocol was designed to collect clinical and family history data, and to use this information to clarify the clinical distinctions between diagnoses. Through mutational analysis for genes known to cause the HDCT and identification of new genes, the study aimed to assess the relationship between specific mutations and their associated phenotypes, an effort that is ongoing (Shalhub et al., 2014) . 
| Study design

| Recruitment and consent methods
Participants were recruited from the pool of patients previously seen by the Principal Investigators and from patient support groups nationally. Most participants were diagnosed by a clinical geneticist prior to participating in the study. In a small number the diagnosis was suggested by the primary care doctor or a specialist such as an orthopedic surgeon or a rheumatologist. Specific efforts were made to recruit minority participants. Recruitment letters were sent to minority medical institutions and practitioners who practice in areas with high minority populations. Efforts were made to collect biological samples from individuals with connective tissue disorders of unknown genetic cause. An authorized guardian provided consent for minor participants, with age-appropriate assent by the minor.
Participants were re-contacted by a coauthor (SM) to ascertain their willingness to be approached for participation in follow-up assessments and future studies. All but one contacted participant agreed to be re-contacted in the future.
| Inclusion criteria 2.4.1 | Demographics
Both genders were recruited for participation. Full clinical assessments were performed beginning at age 12 with no upper age limit. Biological samples were contributed by participants as young as age 2. 
| Clinical eligibility
Relatives
Both affected and unaffected relatives contributed biological samples.
These were primarily first degree relatives of the probands but in some cases more extended family members were included.
| Exclusion criteria
The major exclusion criterion was the inability to provide informed consent or the absence of a guardian who was authorized to provide informed consent in the case of minor subjects. Pregnant and nursing women were limited in their participation in some aspects of the study (e.g., ionizing radiation exposure or MRI) during the time they were pregnant/nursing. This study did not enroll individuals with cognitive disabilities or with cytogenetic findings establishing an alternative diagnosis.
| Clinical evaluation
Affected participants were admitted to the NIA-ASTRA unit for up to 3 days for testing and sample collection. The scope of clinical assessment for affected and unaffected individuals is catalogued in Section 3. Data collection forms for the following study elements are provided in Supporting Information
| Demographics
Age at visit, gender, self-reported ethnicity/race.
| Narrative history
Detailed narrative history, including medical and surgical histories and medication use. Verification of patient history through independent review of medical records was not routinely performed.
| Physical examination
The physical examination included orthostatic blood pressure and pulse measurements, a standardized Beighton score for joint hypermobility and a skin exam to assess for skin texture, translucency, and extensibility. Elements of the diagnostic criteria for Marfan syndrome and Stickler syndrome were included if these diagnoses were suspected by the evaluating clinician.
| Medical photography
The IRB included consent for medical photography. Images are not part of the dataset.
| Laboratory studies
Complete Blood Count Panel, Chemistry Panel, Urinalysis, Hormone Analysis.
| Diagnostic studies
Electrocardiogram, echocardiogram, holter monitoring during wakefulness and sleep, pulse wave velocity, ankle-brachial index, dual-energy x-ray absorptiometry (DEXA) bone densitometry, magnetic resonance imaging (MRI, supine, neutral position, brain, neck, chest), and magnetic resonance angiography (MRA, brain). 
| Patient reported outcome measures
| Biosamples
Volar forearm skin biopsies were performed and fibroblasts isolated in culture and frozen in liquid nitrogen. Plasma, saliva, and urine samples were also collected. One investigator (NM) was able to obtain a limited number of surgical samples, primarily of vascular tissue or bone.
Samples were directly collected in the operating room and immediately processed and archived.
| Diagnostic assignment
Consented participants were initially classified based on diagnostic criteria in place at the time of their clinical visit at the NIA (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) .
Subjects contributing only biological samples were diagnosed either through a limited onsite evaluation or through review of submitted medical records.
| Reclassification
Between 2013 and 2015, clinical research forms were constructed to verify the assignment to one of the following diagnostic categories: EDS (subtypes: classical, hypermobile, vascular, rare and unclassified), Marfan syndrome, Stickler syndrome, FMD, HDCT Other. These classifications were based on the diagnostic criteria that were in place when the research subjects were enrolled, as described below:
| Ehlers-Danlos syndrome (EDS)
Extensive clinical and genetic heterogeneity characterize the 13 types of EDS, but as a whole they are characterized by joint hypermobility, skin hyperextensibility, and vascular and soft tissue fragility, with varying involvement of different organ systems in the different types.
At the time of their initial NIA clinical assessment, patients with EDS were classified according to the Villefranche Nosology (Beighton, De Paepe, Steinmann, Tsipouras, & Wenstrup, 1998) .
| Classical
The diagnosis of classical type of EDS was made on the basis of joint laxity (Beighton score ≥4/9), extremely hyperextensible skin, fragility of the skin with evidence of easy bruising, and the presence of thin atrophic scars.
| Hypermobile
The diagnosis of hypermobile EDS was made on the basis of a history or presence of dislocations, generalized joint laxity, and velvety texture of skin with an absence of extreme skin extensibility and profoundly abnormal scars.
| Vascular
The diagnosis of vascular EDS was made based on genetic testing showing causative variants in COL3A1, the gene encoding Type III collagen.
| Rare and Unclassified
This category included patients with the rarer types of EDSs. A molecular diagnosis was used for the arthrochalasia and kyphoscoliotic types. Some patients had features overlapping with two or more types of EDS, and classification proved to be difficult in those cases, and such patients were diagnosed as "EDS, unclassified." If we had a clinical impression of EDS but they did not meet the diagnostic criteria for any of the known types, we assigned a diagnosis of "EDS, unclassified." Participants in this group may be reclassified as new genetic causes are found (Blackburn et al., 2018) .
| Marfan syndrome
Marfan syndrome is an autosomal dominant systemic connective tissue disorder caused by defects in fibrillin 1, a major component of elastic tissue (Dietz et al., 1991; Lee et al., 1991) . Current nosology states that the major clinical criteria are aneurysmal dilation of the ascending aorta and dislocation of the ocular lenses (Loeys et al., 2010) 
| Stickler syndrome (hereditary arthoopthalmopathy)
This is an autosomal dominant disorder characterized by ocular, oralfacial, auditory, cardiac, and skeletal abnormalities, including premature osteoarthritis, vitreo-retinal degeneration that may lead to retinal detachment, and sensorineural hearing loss. Genetic defects have been found in the genes encoding Type II collagen and Type XI collagen. Substantial clinical variation within and between families is noted (Francomano, 2010; Francomano et al., 1987; Liberfarb et al., 2003 
| Fibromuscular dysplasia
FMD is a rare, nonatherosclerotic vascular disease, originally described in 1938 (Leadbetter & Burkland, 1938) , characterized by arterial dysplasia and obstruction to arterial blood flow by neointimal lesions rich with cells with a smooth muscle phenotype (Slovut & Olin, 2004) . It most commonly affects the renal arteries (presenting as hypertension) and internal carotid arteries (presenting as stroke or transient ischemic attack) but has been described in virtually all arterial beds. Ganesh et al first recognized this as a generalized connective tissue disorder (Ganesh et al., 2014) .
| HDCT other (overlapping connective tissue disorder)
The HDCT group is heterogenous and contains multiple diverse families. Efforts continue to further refine phenotypes and identify genetic loci. We identified a family with a new autosomal dominant connective tissue disorder with features overlapping those of Ehlers-Danlos, Marfan, and Stickler syndromes, which we initially labeled Overlapping Connective Tissue Disorder." During the course of the study, a number of other families with similar features were identified. One subset of this phenotype was found by Hal Dietz and his colleagues to be caused by mutations in the TGFB2 gene and is now recognized as a subtype of Loeys-Dietz syndrome (Lindsay et al., 2012) . It is likely that analyses will identify additional explanatory mutations.
| NIA repository structure
The NIA cohort data is stored in a relational database repository and 
| Biorepository donations
Data and biosamples from a subset of participants were contributed to two national repositories, Corriel and GenTAC (National Registry of Genetically Triggered Thoracic Aortic Aneurysms and other Cardiovascular Conditions).
| RESULTS
| NIA HDCT cohort
The HDCT NIA Dataset v.2016 consented cohort includes 1,009 participants with an average age of 39 ± 18 years (range 2-95, median 40). One hundred ninety-four participants were 18 years or younger.
Demographic characteristics of the cohort by diagnostic category are shown in Table 1 . 
| Multiple visits
| National repositories: Coriell and GenTAC
One hundred twenty-six samples were contributed to the Coriell Tis- Table 3 shows the data elements in the transferred repository. After reviewing the elements in the data repository, the Penn State EDS patient research advisory group identified four areas for initial focus:
| PSU CTSI NIA HDCT data repository
(a) difficulties with nighttime sleep and daytime fatigue; (b) pain, (c) differences in disease manifestations among EDS types, and (d) the multisystem nature of their condition. The datasets were cleaned and descriptive and summary statistics were computed. Various questionnaires were scored according to published guidelines. We are currently prioritizing the creation of structured data elements from the unstructured data.
| Derived projects and publications
The NIA HDCT data have contributed to advances in understanding familial hypertryptasemia (Chovanec et al., 2017; Lyons et al., 2016) .
Clinical characterization and molecular studies of the NIA FMD cohort were included in the publication showing clinical and biochemical profiles that suggested FMD is a systemic disease with altered TGF-β expression and connective tissue features. (Ganesh et al., 2014) .
| DISCUSSION
The heritable HDCT are a group of high morbidity, high-diseaseburden conditions, many of which are underdiagnosed and poorly understood. The NIA HDCT research repository and the developing plans for its dissemination and use are the product of a concerted effort among researchers, clinicians, patient partners, and advocacy organizations to address both the challenges and opportunities provided by this group of rare diseases.
Unlike organ-specific diseases (e.g., lung disease, heart disease) heritable HDCT affect multiple organ systems, a reflection of the ubiquity of connective tissue throughout the body. This multiorgan system manifestation presents a particular challenge for defining and studying a disease and can slow the adoption and evaluation of diagnostic criteria. In other diseases such as cystic fibrosis, genetic analysis has shown the importance of disease modifiers, as a single genotype can be expressed very differently in two individuals depending on the presence or absence of modifier alleles (Cutting, 2010) . This may also be the case in many of the HDCTs. Another continuing challenge is defining the disease phenotypes for these rare disorders because a phenotype that is thought to be a single entity, may in fact represent multiple conditions, each with a distinct, but overlapping presentation and trajectory.
The NIA HDCT repository has continuing value as diagnostic classifications evolve. The biorepository combined with the rich phenotypic data set can be used to evaluate the impact of new nosologies.
For example, the 2017 International EDS Classification diagnostic criteria now recognize 13 subtypes based on clinical criteria and organize the subtypes into a pathogenetic schema based on causative protein functions . The NIA repository can now be assessed to determine the impact of the reclassification and new diagnostic criteria for different types of EDS.
Construction of this dataset, and the process of making it available to interested investigators, reflects lessons from work in other rare diseases. Assembling cohorts of patients with similar presentations, albeit of unknown cause, is the first step in gene discovery, which may result in the identification of new pathogenic pathways and lead to development of rational therapies where none are now available (Griggs et al., 2009; Habashi et al., 2006) . Structured approaches to characterizing a rare disease with detailed phenotyping can be the first step to developing a more limited set of common data elements that form the basis for prognostic instruments and for evaluating interventions, whether pharmacotherapies or disease management strategies (Corvol et al., 2015; Cutting, 2015; NINDS Common Data Elements, 2018) .
In the case of the HDCT, especially EDS, increasing recognition of the overlap between various phenotypes and co-morbidities, has led to the development of the EDS Co-Morbidity Coalition of patient Ideally, an equal number of men and women would have been enrolled in this study, however, men and ethnic minorities were under-represented in the patient population. Although gender ratio for these disorders should be 1:1, female patients with hypermobile EDS are well-known to be over-represented in genetics clinics and research cohorts (Murray, Yashar, Uhlmann, Clauw, & Petty, 2013) .
Affected females, on average, seem to have more severe manifestations and consequently seek medical attention more frequently than men . It is possible that the female predominance beginning in adolescence reflects hormonal influences or epigenetic modification of a common genotype.
Although the original longitudinal study of the NIA cohort was not fully completed as planned, a robust cross-sectional clinical dataset has emerged, with some limited longitudinal data. Over a decade has passed since the initial clinical assessment of many participants.
The persons in the cohort have been approached and are overwhelmingly willing to be re-contacted concerning future research about the HDCT. This offers the opportunity for longitudinal re-assessment of the cohort, supplementing the baseline assessment with additional phenotyping. In keeping with the goals of the original NIA study, the PSU CTSI is performing extensive analyses of the EDS Cohort (HDCT NIA Dataset v.2016). We anticipate that this article, which provides a Mini-mental examination (as necessary; Folstein, Folstein, and McHugh, 1975; Tombaugh & McIntyre, 1992) Structured (text) NEO personality inventory (Costa Jr. & McCrae, 1985 basic description of the cohort and available data, is the first of many prepared by the PSU EDS study group utilizing the NIA HDCT data set.
The study of genetic materials, tissue samples, and clinical data from patients with HDCT can increase insight into common pathological conditions that affect the aging population, since specific manifestations are models of organ specific aging. These manifestations include osteopenia/osteoporosis, osteoarthritis, degenerative disc disease, arterial aneurysms, musculoskeletal disability (weakness and 
